Compare PCM & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCM | BDSX |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 88.3M |
| IPO Year | N/A | 2020 |
| Metric | PCM | BDSX |
|---|---|---|
| Price | $6.04 | $10.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 29.1K | ★ 4.2M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,173,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | N/A | $26.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $6.88 | $3.44 |
| 52 Week High | $10.20 | $21.60 |
| Indicator | PCM | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 57.77 |
| Support Level | $5.99 | $8.69 |
| Resistance Level | $6.04 | $11.49 |
| Average True Range (ATR) | 0.05 | 1.70 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 38.83 | 54.78 |
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.